Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Slides:

Advertisements

Similar presentations

Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Advertisements

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Fibroblast activation in WT and NFATc2-deficient mice.

Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Splenic CD169+ macrophages trap and prevent early Lm replication and spread. Splenic CD169+ macrophages trap and prevent early Lm replication and spread.

FIP200 deficiency alters mitochondria activation and ROS production in T cells. FIP200 deficiency alters mitochondria activation and ROS production in.

CD8α+ DC-deficient mice are highly susceptible to Lm infection in the absence of CD169+ macrophages. CD8α+ DC-deficient mice are highly susceptible to.

CD169+ macrophages play a critical role in mediating innate immune cell reorganization. CD169+ macrophages play a critical role in mediating innate immune.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Cytotoxic therapy induces CSF1-dependent macrophage recruitment.

CD169+ macrophages mediate Lm translocation to the splenic T cell zones. CD169+ macrophages mediate Lm translocation to the splenic T cell zones. (A) Confocal.

Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. NAC in breast cancer patients promotes TMEM assembly and.

Cytosolic entry of Lm required for CD8α+ DC recruitment.

NRP1-expressing myeloid cells influence adipocyte hypertrophy, development of fatty liver, and CLSs. NRP1-expressing myeloid cells influence adipocyte.

Genetic FIP200 deletion impairs autophagy induction and causes T cell apoptosis. Genetic FIP200 deletion impairs autophagy induction and causes T cell.

Fig. 7 Correlation of NHP and human ISGs.

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

Low accessibility to Ag for CTLs leads to low proliferation of effectors. Low accessibility to Ag for CTLs leads to low proliferation of effectors. Intravital.

Immune cell recruitment after the NIR-boosted and MN-mediated cancer immunotherapy. Immune cell recruitment after the NIR-boosted and MN-mediated cancer.

Fig. 5 Hypoxic tumors from obese mice associate with increased production of IL-6 by adipocytes and myeloid cells. Hypoxic tumors from obese mice associate.

Cell viability tests. Cell viability tests. SEM images of (A) MC3T3-E1 cells and (B) MSCs on days 1, 3, and 5 of culture. (C) Survival rates of MC3T3-E1.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

CD169+ macrophages mediate the transport of bacteria to T cell zones by trans-infecting CD8α+ DCs. CD169+ macrophages mediate the transport of bacteria.

Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.

Fig. 6. Nontaxane chemotherapies induce TMEM-dependent prometastatic changes in the breast cancer microenvironment. Nontaxane chemotherapies induce TMEM-dependent.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Genetic EGFR ablation in K-RAS–mutated lung AC reduces tumor growth

Vaccine MN confer protective innate and adaptive immunity.

Fig. 3 NK cells are enriched in ICB-sensitive tumors in mouse models and patients and are required for response. NK cells are enriched in ICB-sensitive.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Fig. 1 Inbred mouse strains carrying monoclonal tumors display a symmetrical yet disparate response to ICB, associated with a distinctive gene signature.

Fig. 4 Rational therapeutic modulation of the tumor microenvironment sensitizes tumors to ICB. Rational therapeutic modulation of the tumor microenvironment.

Fig. 3 BMS blocks functional responses in primary immune cells driven by IL-23 and IL-12. BMS blocks functional responses in primary immune.

Fig. 2 Inflammatory pathways with STAT1 as a key regulator are enriched in ICB responsive tumors in mouse models and patients. Inflammatory pathways with.

BMS blocks functional responses in primary immune cells driven by IFNα

Fig. 5 Treatment with BMS (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS (PO BID) protects from.

Tfr cells respond better to immunization with self-antigens than with foreign antigens. Tfr cells respond better to immunization with self-antigens than.

Fig. 6 RUNX/CBFB interaction inhibitor, Ro5-3335, significantly decreases mouse neurofibroma growth in vivo. RUNX/CBFB interaction inhibitor, Ro5-3335,

S-Affs colocalize with SUMO in mammalian cells.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

AEGIS autonomous targeting process.

Fig. 1. Matrix stiffness sensitizes myofibroblasts to apoptosis induced by inhibition of their mechanotransduction pathways. Matrix stiffness sensitizes.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

Fig. 4. Paclitaxel promotes the expression of invasive isoforms of MENA in the primary breast cancer microenvironment. Paclitaxel promotes the expression.

Representative CT and PET/CT images of three patients with NSCLCs

PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models

Pharmacological targeting of CDs promotes response to KRASG12C inhibition in vivo. Pharmacological targeting of CDs promotes response to KRASG12C inhibition.

Fig. 5. Vascularization of human liver seed grafts.

Fig. 4 IP6K1-mediated polyP production by platelets plays a critical role in LPS-induced NPA formation. IP6K1-mediated polyP production by platelets plays.

Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9.

Fig. 2 Increasing KLF17, CDH1, and LASS2 expression reduced malignant progression and promoted apoptosis of tumor cells. Increasing KLF17, CDH1, and LASS2.

Fig. 8. TIE2 inhibitor rebastinib eliminates the prometastatic effects of paclitaxel. TIE2 inhibitor rebastinib eliminates the prometastatic effects of.

Fig. 5. High burdens of AA signature mutations and predicted immunogenicity in Taiwan HCCs. High burdens of AA signature mutations and predicted immunogenicity.

AV3 potentiates the effect of gemcitabine in the PDX model in mice

Fibroblast activation in WT and NFATc2-deficient mice.

Fig. 7 BEL immune response.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.

Fig. 3 Superiority of BAFF-R versus CD19-CAR T cells in a Burkitt lymphoma model is not due to greater tumor antigen density. Superiority of BAFF-R versus.

Fig. 2 Supraballs and films from binary SPs.

Fig. 5 The complex of antibody and dye can afford to target imaging in the NIR-II window. The complex of antibody and dye can afford to target imaging.

Fig. 3 Minimal treatment of ETL decreases metastatic burden and prolongs survival in the 4T1 breast carcinoma model after tumor resection. Minimal treatment.

Fig. 6 Pharmacologic alterations of β-AR signaling regulate cardiomyocyte abscission and endowment. Pharmacologic alterations of β-AR signaling regulate.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

In vivo function of MeTro sealants using rat incision model of lungs

Fig. 5. Paclitaxel promotes breast cancer cell dissemination and metastasis in a MENA-dependent manner. Paclitaxel promotes breast cancer cell dissemination.

Fig. 6 tlr2 is necessary for SASP activation in vivo.

Fig. 5 Controlled tumor growth inhibition study of the self-assembled nanostructures. Controlled tumor growth inhibition study of the self-assembled nanostructures.

Presentation transcript:

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. (A) Experimental design and chemotherapy scheme. i.v., intravenously. (B) Mouse models of breast carcinoma, estrogen receptor (ER) status in each model, and cohort sizes. (C) Tumor volume quantification on day 15 of the chemotherapy scheme shown in (A). Mann-Whitney U test. (D) TMEM score, assessed in 10 high-power fields (HPFs) by two pathologists, in mice treated as shown in (A). Mann-Whitney U test. (E) TMEM identification by triple-stain immunohistochemistry (IHC) and representative images for each mouse model. Scale bar, 50 μm. (F) Perivascular IBA1+ macrophages (Mϕ) in 10 HPFs (absolute counts) in PyMT spontaneous and HT17 xenograft tumors, treated with paclitaxel or vehicle control. Mann-Whitney U test. (G) Perivascular TIE2hi/VEGFhi macrophages in 10 HPFs (absolute counts) quantified in PyMT spontaneous and HT17 xenograft tumors, treated with paclitaxel or vehicle control. Mann-Whitney U test. (H) Multichannel IF of IBA1, CD31, TIE2, VEGF, and 4′,6-diamidino-2-phenylindole (DAPI) in two sequential sections of an MMTV-PyMT breast tumor not treated with paclitaxel. Representative VEGFhi/TIE2hi macrophage (also coexpressing IBA1) is encircled with yellow dotted line. Scale bar, 10 μm. (I) Multichannel IF of IBA1, CD31, VEGF, and DAPI in an HT17 xenograft tumor, treated with paclitaxel, demonstrating one VEGFhi and one VEGFlo macrophage in a field. Scale bar, 15 μm. (J and K) Correlations of macrophage infiltration (IBA1+ macrophages or VEGFhi/TIE2hi macrophages) with TMEM score in the PyMT spontaneous (J) and HT17 xenograft (K) models. R2 = Pearson’s coefficient of determination; filled circles, control; open circles, paclitaxel. George S. Karagiannis et al., Sci Transl Med 2017;9:eaan0026 Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works